Is MoonLake Immunotherapeuti Stock a Good Investment?
MoonLake Immunotherapeuti Investment Advice | MLTX |
- Examine MoonLake Immunotherapeuti's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research MoonLake Immunotherapeuti's leadership team and their track record. Good management can help MoonLake Immunotherapeuti navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact MoonLake Immunotherapeuti's business and its evolving consumer preferences.
- Compare MoonLake Immunotherapeuti's performance and market position to its competitors. Analyze how MoonLake Immunotherapeuti is positioned in terms of product offerings, innovation, and market share.
- Check if MoonLake Immunotherapeuti pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about MoonLake Immunotherapeuti's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in MoonLake Immunotherapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if MoonLake Immunotherapeutics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine MoonLake Immunotherapeuti Stock
Researching MoonLake Immunotherapeuti's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 15.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.89. MoonLake Immunotherapeuti had not issued any dividends in recent years.
To determine if MoonLake Immunotherapeuti is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MoonLake Immunotherapeuti's research are outlined below:
| MoonLake Immunotherapeuti generated a negative expected return over the last 90 days | |
| MoonLake Immunotherapeuti has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (121.24 B) with profit before overhead, payroll, taxes, and interest of 0. | |
| MoonLake Immunotherapeutics currently holds about 92.71 M in cash with (116.59 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.51. | |
| MoonLake Immunotherapeuti has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: MoonLake Immunotherapeutics Earns Outperform Rating from Analysts at Royal Bank of Canada |
MoonLake Immunotherapeuti uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MoonLake Immunotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MoonLake Immunotherapeuti's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 18th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 18th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact MoonLake Immunotherapeuti's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises MoonLake Immunotherapeuti's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-07 | 2024-03-31 | -0.19 | -0.22 | -0.03 | 15 | ||
2023-08-10 | 2023-06-30 | -0.27 | -0.23 | 0.04 | 14 | ||
2023-11-14 | 2023-09-30 | -0.23 | -0.18 | 0.05 | 21 | ||
2022-11-14 | 2022-09-30 | -0.32 | -0.27 | 0.05 | 15 | ||
2023-05-12 | 2023-03-31 | -0.31 | -0.23 | 0.08 | 25 | ||
2024-08-07 | 2024-06-30 | -0.28 | -0.39 | -0.11 | 39 | ||
2024-02-29 | 2023-12-31 | -0.23 | -0.12 | 0.11 | 47 | ||
2024-11-12 | 2024-09-30 | -0.44 | -0.56 | -0.12 | 27 |
MoonLake Immunotherapeuti Target Price Consensus
MoonLake target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. MoonLake Immunotherapeuti's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 15 | Strong Buy |
Most MoonLake analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand MoonLake stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of MoonLake Immunotherapeuti, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMoonLake Immunotherapeuti Target Price Projection
MoonLake Immunotherapeuti's current and average target prices are 39.00 and 76.33, respectively. The current price of MoonLake Immunotherapeuti is the price at which MoonLake Immunotherapeutics is currently trading. On the other hand, MoonLake Immunotherapeuti's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
MoonLake Immunotherapeuti Market Quote on 27th of March 2025
Target Price
Analyst Consensus On MoonLake Immunotherapeuti Target Price
MoonLake Immunotherapeuti Analyst Ratings
MoonLake Immunotherapeuti's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about MoonLake Immunotherapeuti stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of MoonLake Immunotherapeuti's financials, market performance, and future outlook by experienced professionals. MoonLake Immunotherapeuti's historical ratings below, therefore, can serve as a valuable tool for investors.Know MoonLake Immunotherapeuti's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MoonLake Immunotherapeuti is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MoonLake Immunotherapeutics backward and forwards among themselves. MoonLake Immunotherapeuti's institutional investor refers to the entity that pools money to purchase MoonLake Immunotherapeuti's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Marshall Wace Asset Management Ltd | 2024-12-31 | 1.2 M | Polar Capital Holdings Plc | 2024-12-31 | 1.1 M | Alliancebernstein L.p. | 2024-12-31 | 1 M | Fred Alger Management, Llc | 2024-12-31 | 673.8 K | Hood River Capital Management Llc | 2024-12-31 | 649.6 K | Nuveen Asset Management, Llc | 2024-12-31 | 595.6 K | Ing Investment Management Llc | 2024-12-31 | 448.9 K | Finepoint Capital Lp | 2024-12-31 | 447.9 K | Camber Capital Management Llc | 2024-12-31 | 441 K | Bvf Inc | 2024-12-31 | 19.8 M | Cormorant Asset Management, Llc | 2024-12-31 | 8.5 M |
MoonLake Immunotherapeuti's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.51 B.Market Cap |
|
MoonLake Immunotherapeuti's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.27) | |
| Return On Capital Employed | (0.12) | (0.11) | |
| Return On Assets | (0.25) | (0.27) | |
| Return On Equity | (0.27) | (0.26) |
Determining MoonLake Immunotherapeuti's profitability involves analyzing its financial statements and using various financial metrics to determine if MoonLake Immunotherapeuti is a good buy. For example, gross profit margin measures MoonLake Immunotherapeuti's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MoonLake Immunotherapeuti's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in MoonLake Immunotherapeuti's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MoonLake Immunotherapeutics. Check MoonLake Immunotherapeuti's Beneish M Score to see the likelihood of MoonLake Immunotherapeuti's management manipulating its earnings.
Evaluate MoonLake Immunotherapeuti's management efficiency
MoonLake Immunotherapeuti has return on total asset (ROA) of (0.1781) % which means that it has lost $0.1781 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2508) %, meaning that it created substantial loss on money invested by shareholders. MoonLake Immunotherapeuti's management efficiency ratios could be used to measure how well MoonLake Immunotherapeuti manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2025. Return On Capital Employed is likely to rise to -0.11 in 2025. At this time, MoonLake Immunotherapeuti's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 3.8 B in 2025, whereas Other Assets are likely to drop 0.80 in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.2 K | 7.6 K | |
| Tangible Book Value Per Share | 7.2 K | 7.6 K | |
| Enterprise Value Over EBITDA | (41.90) | (44.00) | |
| Price Book Value Ratio | 0.01 | 0.01 | |
| Enterprise Value Multiple | (41.90) | (44.00) | |
| Price Fair Value | 0.01 | 0.01 | |
| Enterprise Value | 3.2 B | 3.4 B |
Understanding the operational decisions made by MoonLake Immunotherapeuti management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Beta 1.304 |
Basic technical analysis of MoonLake Stock
As of the 27th of March, MoonLake Immunotherapeuti secures the Mean Deviation of 2.33, risk adjusted performance of (0.14), and Standard Deviation of 2.88. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MoonLake Immunotherapeuti, as well as the relationship between them.MoonLake Immunotherapeuti's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MoonLake Immunotherapeuti insiders, such as employees or executives, is commonly permitted as long as it does not rely on MoonLake Immunotherapeuti's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MoonLake Immunotherapeuti insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
MoonLake Immunotherapeuti's Outstanding Corporate Bonds
MoonLake Immunotherapeuti issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MoonLake Immunotherapeuti uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MoonLake bonds can be classified according to their maturity, which is the date when MoonLake Immunotherapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand MoonLake Immunotherapeuti's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing MoonLake Immunotherapeuti's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (3.46) | |||
| Mean Deviation | 2.33 | |||
| Coefficient Of Variation | (590.16) | |||
| Standard Deviation | 2.88 | |||
| Variance | 8.29 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | (3.47) | |||
| Maximum Drawdown | 10.73 | |||
| Value At Risk | (5.09) | |||
| Potential Upside | 4.16 | |||
| Skewness | (0.03) | |||
| Kurtosis | (0.45) |
| Risk Adjusted Performance | (0.14) | |||
| Market Risk Adjusted Performance | (3.46) | |||
| Mean Deviation | 2.33 | |||
| Coefficient Of Variation | (590.16) | |||
| Standard Deviation | 2.88 | |||
| Variance | 8.29 | |||
| Information Ratio | (0.17) | |||
| Jensen Alpha | (0.50) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | (3.47) | |||
| Maximum Drawdown | 10.73 | |||
| Value At Risk | (5.09) | |||
| Potential Upside | 4.16 | |||
| Skewness | (0.03) | |||
| Kurtosis | (0.45) |
Consider MoonLake Immunotherapeuti's intraday indicators
MoonLake Immunotherapeuti intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MoonLake Immunotherapeuti stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
MoonLake Immunotherapeuti Corporate Filings
F4 | 3rd of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 26th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
| 12th of February 2025 Other Reports | ViewVerify |
MoonLake Stock media impact
Far too much social signal, news, headlines, and media speculation about MoonLake Immunotherapeuti that are available to investors today. That information is available publicly through MoonLake media outlets and privately through word of mouth or via MoonLake internal channels. However, regardless of the origin, that massive amount of MoonLake data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MoonLake Immunotherapeuti news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MoonLake Immunotherapeuti relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MoonLake Immunotherapeuti's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MoonLake Immunotherapeuti alpha.
MoonLake Immunotherapeuti Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards MoonLake Immunotherapeuti can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
MoonLake Immunotherapeuti Historical Investor Sentiment
Investor biases related to MoonLake Immunotherapeuti's public news can be used to forecast risks associated with an investment in MoonLake. The trend in average sentiment can be used to explain how an investor holding MoonLake can time the market purely based on public headlines and social activities around MoonLake Immunotherapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
MoonLake Immunotherapeuti's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for MoonLake Immunotherapeuti and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average MoonLake Immunotherapeuti news discussions. The higher the estimate score, the more favorable the investor's outlook on MoonLake Immunotherapeuti.
MoonLake Immunotherapeuti Maximum Pain Price Across June 20th 2025 Option Contracts
MoonLake Immunotherapeuti's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of MoonLake Immunotherapeuti close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of MoonLake Immunotherapeuti's options.
MoonLake Immunotherapeuti Corporate Management
| Tino Anthamatten | Market Marketing | Profile | |
| Luciana Marques | People HR | Profile | |
| Jorge Silva | CEO CoFounder | Profile | |
| Nicolas Mosimann | General Counsel | Profile | |
| Oliver Daltrop | Chief Officer | Profile |
Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.